BRIEF-AbbVie says interested in smaller "tuck in" acquisitions

Wed Jan 30, 2013 9:39am EST

Jan 30 (Reuters) - AbbVie Inc : * Sees additional $1 billion in sales over next 5 years from emerging markets * Says expects androgel sales in 2013 to grow by double digit percentage range * Says expects flat lupron sales in 2013, compared with 2012 * Says expects 2013 synthroid sales to grow in mid-single digit percentage

range * Says expects 2013 company sales somewhat above $18 billion * Says expects 2013 research and development spending to be about 14.5 percent

of company sales * Says expects 2013 tax rate of 22 percent * Says expects Q1 EPS, excluding special items, of $0.64 to $0.66 * Says expects negative foreign exchange impact of 1 percent in 2013 * Interested in smaller "tuck in" acquisitions, not large deals * Says expects "robust" growth of humira arthritis drug for forseeable future * Says expects new drugs to drive company growth by second half of 2015

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.